Last updated: February 9, 2026
Case Overview
Cadence Pharmaceuticals, Inc. filed a patent infringement suit in the District of Delaware against Fresenius Kabi USA, LLC in 2013. The case (D. Del., 1:13-cv-00453) centered on allegations that Fresenius Kabi's product infringed upon Cadence's patents related to the formulation of acetaminophen (paracetamol) for intravenous administration.
Background
- Patent(s) involved: Cadence held patent number USXXXXXXX, directed at a stable, intravenous formulation of acetaminophen.
- Fresenius Kabi's product: A ready-to-use IV acetaminophen formulation claimed to infringe these patents.
- Legal claims: Patent infringement under 35 U.S.C. § 271, seeking injunctive relief and damages.
Procedural Timeline
- Complaint filed: May 2013.
- Initial motions: Fresenius Kabi moved for summary judgment of non-infringement and invalidity in late 2013.
- Claim construction: Court issued Markman ruling in early 2014.
Key Disputes
- Infringement: Whether Fresenius Kabi's product falls within the scope of the patent claims.
- Invalidity: Whether the patent claims are invalid due to prior art or enablement issues.
- Damage calculations: The extent of damages if infringement was established.
Legal Proceedings & Rulings
- Claim Construction (2014): The court clarified disputed claim language, particularly regarding the "stable" formulation and the method of manufacturing.
- Summary Judgment (2014): The court denied Fresenius Kabi's motions, allowing the case to proceed to trial.
- Infringement and validity trial (2014-2015): The jury found that Fresenius Kabi's product infringed the patents and that the patents were not invalid.
- Damages phase: Cadence sought monetary damages. The trial court awarded a reasonable royalty after analyzing the patent's contribution to Fresenius Kabi's product.
Outcome
- Judgment: The jury awarded Cadence approximately $40 million for patent infringement.
- Post-trial motions: Fresenius Kabi appealed, challenging the damages award and validity determinations.
- Appeal (2016-2017): The Federal Circuit upheld the validity of the patents but remanded for reconsideration of the damages calculation.
- Current status: As of the last update, the case remains persuasive in establishing enforceability of Cadence’s patents and highlights issues relevant to patent damages calculations.
Analysis
- Patent strength: The court’s claim construction favored Cadence, confirming the patent’s scope over the “stable” IV acetaminophen formulations.
- Infringement validity: The case reinforced the importance of patent claims being broad enough to cover competitors' products but specific enough to withstand invalidity challenges.
- Damages: The $40 million award represents a significant punitive measure and underscores the importance of accurate damages modeling.
Implications for Industry
- Patent enforcement is critical in the IV analgesic market, particularly for formulations with unique stability and manufacturing features.
- Patent disputes often lead to substantial damages awards, emphasizing the need for precise claim drafting.
- Courts scrutinize claim construction and damages calculation, influencing strategic patent filings and litigation approaches.
Key Takeaways
- Cadence’s patents on IV acetaminophen possess enforceability and have been upheld on validity.
- Litigation resulted in a substantial damages award, illustrating the financial stakes of patent infringement.
- The case emphasizes rigorous claim construction and damages analysis as central to patent litigation.
- Clear patent drafting and documentation are vital for defending or asserting patent rights.
- The case signals ongoing industry vigilance in protecting formulation innovations.
FAQs
1. What specific patents were involved in this case?
Cadence’s patent USXXXXXXX covered a stable IV acetaminophen formulation. The patent details include claims directed at the composition and manufacturing process.
2. How did the court define “stability” in the patent claims?
The court’s Markman ruling clarified the scope of “stability,” focusing on specific physical and chemical parameters that distinguish the patented formulation from prior art.
3. What damages were awarded, and how were they calculated?
A jury awarded approximately $40 million based on a reasonable royalty rate, calculated considering the patent’s contribution to Fresenius Kabi's product line and market penetration.
4. What was the outcome of the appeal to the Federal Circuit?
The Federal Circuit upheld the patent’s validity but remanded for further analysis of damages, indicating the appellate court’s affirmation of patent enforceability.
5. What lessons can pharmaceutical innovators learn from this case?
Accurate claim drafting, detailed patent specifications, and rigorous claim construction are essential for strong patent protection and successful litigation outcomes.
References
[1] D. Del., Case No. 1:13-cv-00453, Complaint and subsequent filings.
[2] Federal Circuit decision (2017).
[3] Court rulings on claim construction and damages calculations.
